Masitinib, a c‐kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid‐dependent asthmatics

Background:  Masitinib is a tyrosine kinase inhibitor targeting stem cell factor receptor (c‐kit) and platelet‐derived growth factor (PDGF) receptor, which are expressed on several cell types including mast cells and bronchial structural cells, respectively. We hypothesized that c‐kit and PDGF receptor inhibition may decrease bronchial inflammation and interfere with airway remodeling, which are crucial features of severe asthma.

[1]  P Godard,et al.  Costs of asthma are correlated with severity: a 1-yr prospective study , 2002, European Respiratory Journal.

[2]  K. Sladek,et al.  Treatment of steroid-dependent bronchial asthma with cyclosporin. , 1995, The European respiratory journal.

[3]  Linda Abetz,et al.  Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. , 2006, Respiratory medicine.

[4]  J. Kinet,et al.  Masitinib is safe and effective for the treatment of canine mast cell tumors. , 2008, Journal of veterinary internal medicine.

[5]  W. Busse,et al.  Severe asthma in adults: what are the important questions? , 2007, The Journal of allergy and clinical immunology.

[6]  B. Bain,et al.  Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity , 2006, European Respiratory Journal.

[7]  J. Bousquet,et al.  Biologics in asthma: difficulties and drawbacks. , 2008, Expert opinion on biological therapy.

[8]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[9]  M. Sears,et al.  Asthma exacerbations · 1: Epidemiology , 2006, Thorax.

[10]  S. Holgate,et al.  The mechanisms, diagnosis, and management of severe asthma in adults , 2006, The Lancet.

[11]  N. Barnes,et al.  Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. , 1996, American journal of respiratory and critical care medicine.

[12]  M. Tulliez,et al.  Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. , 2003, Journal of the American Academy of Dermatology.

[13]  C. Hogaboam,et al.  Inhibition of SCF attenuates peribronchial remodeling in chronic cockroach allergen-induced asthma , 2006, Laboratory Investigation.

[14]  J. Bonner,et al.  EGF and PDGF receptor tyrosine kinases as therapeutic targets for chronic lung diseases. , 2006, Current molecular medicine.

[15]  L. Reber,et al.  Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. , 2006, European journal of pharmacology.

[16]  B. Vanhaesebroeck,et al.  Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma , 2008, Nature Medicine.

[17]  M. Humbert,et al.  Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.

[18]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[19]  D. Curran‐Everett,et al.  Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. , 2007, The Journal of allergy and clinical immunology.

[20]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[21]  M. Chen,et al.  Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics , 2008, Circulation.

[22]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.